WHO Grade 3 Glioma — Trials

WHO Grade 3 Glioma — Trials · CancerIndex

Clinical trials

Registered studies

258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 57
Recruiting: 32
Ph III recruiting: 2
Growth YoY: —
Industry share: 11%
Top sponsor: National Cancer Institute (NCI)
Termination share: 39.4%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (53)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07703436	Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease	not yet recruiting	Phase 2	40	Nuvation Bio Inc.INDUSTRY	1	Sep 22, 2026	clinicaltrials
NCT07644312	Study of Relatlimab and Nivolumab (Opdualag) in Replication Repair Deficient HGG and DIPG	not yet recruiting	Phase 2	12	Nationwide Children's HospitalOTHER	0	Sep 9, 2026	clinicaltrials